Radiation and bio-detection technology business, Kromek, says it is on track to deliver significant revenue growth for the full year, as it publishes its interim results for the six months ended 31 October 2021.
The listed Huddersfield-based business has recorded revenues of £4.7m (H1 2021: £4.6m), while its loss before tax reduced to £3.1m (H1 2021: £3.4m loss).
Kromek reports a significant increase in medical imaging new business activity as the impact of the pandemic continued to recede – strengthening its pipeline for H2 2022 and beyond.
Kromek Group plc designs, develops and produces x-ray and gamma-ray imaging and radiation detection products for the medical, CBRNe security, Homeland Security and civil nuclear radiation detection markets.